DARE BIOSCIENCE INC
NASDAQ: DARE (Dare Bioscience, Inc.)
Kemas kini terakhir: 6 jam lalu0.713
-0.03 (-3.65%)
| Penutupan Terdahulu | 0.740 |
| Jumlah Dagangan | 450,194 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.27 |
| Harga / Jualan (P/S) | 8.01 |
| Harga / Buku (P/B) | 29.40 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -18,016.75% |
| EPS Cair (TTM) | -0.170 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 173.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 218.34% |
| Nisbah Semasa (MRQ) | 0.560 |
| Aliran Tunai Operasi (OCF TTM) | 6.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.85 M |
| Pulangan Atas Aset (ROA TTM) | -86.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Dare Bioscience, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.21 |
|
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.57% |
| % Dimiliki oleh Institusi | 9.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Amh Equity Ltd | 30 Sep 2025 | 232,373 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |